Good point re. immune response not simply being a function of mass. However, the doses in the <5yo trial were lower. So let's roll with them for now and boost l

Good point re. immune response not simply being a function of mass. However, the doses in the <5yo trial were lower. So let's roll with them for now and boost later. Sadly @el_benhameen may be correct in the FDA's complacency.